c-Abl Inhibition Exerts Antiparkinsonian Effects by Zhou, Yu et al.
fphar-09-01311 November 14, 2018 Time: 16:52 # 1
PERSPECTIVE
published: 16 November 2018
doi: 10.3389/fphar.2018.01311
Edited by:
Mahmoud Iravani,
University of Hertfordshire,
United Kingdom
Reviewed by:
Ciaran J. Faherty,
Alkermes, United States
Anjali M. Rajadhyaksha,
Weill Cornell Medicine – Cornell
University, United States
*Correspondence:
Satoshi Goto
sgoto@tokushima-u.ac.jp;
sgoto@clin.med.tokushima-u.ac.jp
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 21 August 2018
Accepted: 29 October 2018
Published: 16 November 2018
Citation:
Zhou Y, Yamamura Y, Ogawa M,
Tsuji R, Tsuchiya K, Kasahara J and
Goto S (2018) c-Abl Inhibition Exerts
Symptomatic Antiparkinsonian Effects
Through a Striatal Postsynaptic
Mechanism.
Front. Pharmacol. 9:1311.
doi: 10.3389/fphar.2018.01311
c-Abl Inhibition Exerts Symptomatic
Antiparkinsonian Effects Through a
Striatal Postsynaptic Mechanism
Yu Zhou1,2, Yukio Yamamura1,2, Masatoshi Ogawa1,2, Ryosuke Tsuji1,2,
Koichiro Tsuchiya3, Jiro Kasahara2 and Satoshi Goto1*
1 Department of Neurodegenerative Disorders Research, Institute of Biomedical Sciences, Graduate School of Medical
Sciences, Tokushima University, Tokushima, Japan, 2 Department of Neurobiology and Therapeutics, Institute of Biomedical
Sciences, Graduate School of Pharmaceutical Sciences, Tokushima University, Tokushima, Japan, 3 Department of Medical
Pharmacology, Institute of Biomedical Sciences, Graduate School of Pharmaceutical Sciences, Tokushima University,
Tokushima, Japan
Parkinson’s disease (PD) is caused by a progressive degeneration of nigral dopaminergic
cells leading to striatal dopamine deficiency. From the perspective of antiparkinsonian
drug mechanisms, pharmacologic treatment of PD can be divided into symptomatic
and disease-modifying (neuroprotective) therapies. An increase in the level and activity
of the Abelson non-receptor tyrosine kinase (c-Abl) has been identified in both human
and mouse brains under PD conditions. In the last decade, it has been observed that
the inhibition of c-Abl activity holds promise for protection against the degeneration of
nigral dopaminergic cells in PD and thereby exerts antiparkinsonian effects. Accordingly,
c-Abl inhibitors have been applied clinically as a disease-modifying therapeutic strategy
for PD treatment. Moreover, in a series of studies, including that presented here,
experimental evidence suggests that in a mouse model of parkinsonism induced
by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, c-Abl inhibition exerts an immediate
effect improving motor impairments by normalizing altered activity in striatal postsynaptic
signaling pathways mediated by Cdk5 (cyclin-dependent kinase 5) and DARPP-32
(dopamine- and cyclic AMP-regulated phosphoprotein 32 kDa). Based on this, we
suggest that c-Abl inhibitors represent an ideal antiparkinsonian agent that has both
disease-modifying and symptomatic effects. Future research is required to carefully
evaluate the therapeutic efficacy and clinical challenges associated with applying c-Abl
inhibitors to the treatment of PD.
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INTRODUCTION
c-Abl (Abl1), also known as the Abelson murine leukemia viral oncogene homolog 1, is a member
of the Abl family of non-receptor tyrosine kinases (Colicelli, 2011). As c-Abl is highly conserved
and ubiquitously expressed in multiple mammalian cellular and subcellular components, it likely
plays a role in the regulation of a wide variety of biological processes (Wang, 2014; Khatri et al.,
2016). In the brain, under both normal and pathological conditions, c-Abl tyrosine kinase activity
is linked to diverse neuronal functions related to cellular signaling (Lee et al., 2008; Ko et al., 2010;
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Klein et al., 2011), synapse formation (Finn et al., 2003; Perez de
Arce et al., 2010; Vargas et al., 2014), and neurogenesis (Moresco
and Koleske, 2003; Woodring et al., 2003; Schlatterer et al., 2012).
Observations from the past decade (for a review see,
Brahmachari et al., 2017) indicate that impaired activity of
c-Abl is implicated in the pathogenesis of Parkinson’s disease
(PD), a neurodegenerative disorder caused by the progressive
loss of dopamine (DA)-producing cells in the substantia nigra
(Lotharius and Brundin, 2002; Dauer and Przedborski, 2003;
Lang and Espay, 2018). There is an increase in the level
and activity of c-Abl in human and mouse brains under PD
conditions, which is evidently found in both the substantia nigra
and striatum (Ko et al., 2010; Imam et al., 2011, 2013; Hebron
et al., 2013a; Brahmachari et al., 2016). Experimental evidence
has demonstrated that, in PD conditions, over-activation of
c-Abl might induce parkin dysfunction (Imam et al., 2011;
Gonfloni et al., 2012; Dawson and Dawson, 2014), a-synuclein
aggregation (Hebron et al., 2013a; Mahul-Mellier et al., 2014;
Brahmachari et al., 2016), and impaired autophagy of toxic
elements (Ertmer et al., 2007; Yogalingam and Pendergast,
2008; Xu et al., 2017), leading to the death of the nigral
dopaminergic cells. Accordingly, systemic administration of
c-Abl inhibitors (e.g., imatinib and nilotinib) may hold promise
for protection against the degeneration of nigral dopaminergic
cells in PD and further antiparkinsonian effects (Hebron et al.,
2013a,b; Karuppagounder et al., 2014; Wu et al., 2016; Zhou
et al., 2017; Abushouk et al., 2018). Because antiparkinsonian
drugs available at present do not appear to prevent the
progression of PD, clinical applications of c-Abl inhibitors as
a future disease-modifying therapeutic strategy for PD have
been challenged (Brundin et al., 2013; Lindholm et al., 2016;
Pagan et al., 2016; Brahmachari et al., 2017; Lang and Espay,
2018).
However, in our past studies, we have also demonstrated
that c-Abl inhibitors might modulate striatal phosphorylation of
specific protein targets at the postsynaptic level, and, thereby,
exert antiparkinsonian effects. Abnormal motor behaviors in
PD result from striatal dysfunction due to an imbalance
between dopamine and glutamate transmission, which have
opposing physiological effects (Olanow and Tatton, 1999;
Greengard, 2001). A key regulator of the integration of DA
and glutamate signals is the dopamine- and cyclic AMP-
regulated phosphoprotein 32kDa (DARPP-32) (Greengard,
2001); corticostriatal glutamate inputs activate cyclin-dependent
kinase 5 (Cdk5), which inhibits postsynaptic DA signaling by
phosphorylating DARPP-32 at Thr75 (Bibb et al., 1999). We
previously reported that c-Abl inhibition normalized motor
impairments in a mouse model of PD induced by N-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In this model,
activity of Cdk5 can be inhibited by reducing the phosphorylation
of Cdk5 at Tyr15 (Cdk5-Tyr15), leading to a decreased
phosphorylation of DARPP-32 at Thr75 (DARPP-32-Thr75) in
the striatum (Yamamura et al., 2013; Tanabe et al., 2014). The
present study highlights striatal postsynaptic mechanisms by
which c-Abl inhibitors represent a symptomatic antiparkinsonian
agent to alleviate motor symptoms. Here, we show the immediate
effects of imatinib (STI-571), a first-generation c-Abl inhibitor,
on striatal c-Abl/Cdk5/DARPP-32 signaling pathway and striatal
motor behaviors in MPTP-treated mice.
MATERIALS AND METHODS
Animals
Male C57BL/6 mice (Japan SLC, Shizuoka, Japan) aged 7–8 weeks
were used. The mice were housed under a 12-h light/dark
cycle with ad libitum access to food and tap water. All
experimental procedures were approved by the Committee for
Animal Experiments of Tokushima University.
MPTP Administration
Mice received intraperitoneal (i.p.) injections of MPTP-HCl
(20 mg/kg of free base; Sigma–Aldrich, St. Louis, MO,
United States) dissolved in 0.9% saline, 4 times per day for 1 day
in 2 h-intervals (Tanabe et al., 2014). Saline-treated control mice
received equivalent volumes of 0.9% saline. Our previous work
demonstrated that maximal degenerative effects of MPTP on the
nigral dopaminergic cells were observed when examined 3 days
following MPTP administration (Aoki et al., 2009).
Levodopa Administration
Mice received a single i.p. injection of levodopa (2.5, 5,
or 15 mg/kg of free base; Sigma–Aldrich) dissolved in
0.9% saline containing 0.5% carboxymethyl cellulose 3 days
after administration of MPTP or saline. Vehicle-treated mice
received an equivalent volume of 0.9% saline containing 0.5%
carboxymethyl cellulose. They were pre-treated with a single i.p.
injection of benserazide (12.5 mg/kg; Sigma–Aldrich) dissolved
in 0.9% saline 20 min before administration of levodopa or saline.
Imatinib Administration
Mice received a single i.p. injection of imatinib mesylate (10
or 25 mg/kg; LKT Laboratories, St. Paul, MN, United States)
dissolved in 0.9% saline containing 10% dimethyl sulfoxide 3 days
after the administration of MPTP or saline. Vehicle-treated mice
received an equivalent volume of 0.9% saline containing 10%
dimethyl sulfoxide.
Behavioral Tests
The beam-walking test evaluates motor coordination and balance
in rodents. The testing apparatus consists of a rough round
horizontal beam (wood, 8-mm-diameter for test trials or
16-mm-diameter for training trials, 80 cm long) fixed 60 cm
above a countertop, and a dark goal box (15 cm wide, 10 cm
long, and 10 cm tall). Mice were trained to traverse the beam
without stopping on the way for three consecutive days before
MPTP administration. In test trials, mice were made to traverse
the beam in the same manner. The traveling time from the start
to the 50-cm point was recorded (trials were cut-off at 60 s).
The rota-rod test evaluates motor coordination and motor
learning. The Rota-Rod Treadmill (Constant Speed Model, Ugo
Basile, Varese, Italy) was used. On the day prior to the first
training session, mice were habituated to the apparatus for 5 min.
Frontiers in Pharmacology | www.frontiersin.org 2 November 2018 | Volume 9 | Article 1311
fphar-09-01311 November 14, 2018 Time: 16:52 # 3
Zhou et al. c-Abl Inhibition Exerts Antiparkinsonian Effects
Mice were trained to run on the rota-rod for 10 min at 20 rpm
without falling, twice a day for three consecutive days before
MPTP administration. In the test trials, mice were made to run
on rod at 28 rpm (trials were cut-off at 600 s). The latency to fall
was recorded.
High Performance Liquid
Chromatography (HPLC) Analysis
Mice were sacrificed by cervical dislocation 30 min after
administration of imatinib or vehicle. Striatal tissues and plasma
were rapidly sampled on ice and kept at −80◦C until use. They
were homogenized by glycine buffer (100 µM) at pH 2.75.
Further, an Oasis PRiME Lipophilic Balance extraction cartridge
(Waters Corporation, Milford, MA, United States) was used to
extract imatinib from the tissues (Miura et al., 2011). HPLC
analysis was conducted using an 880-PU Intelligent HPLC pump
equipped with an 875-UV Intelligent UV/Vis detector (Jasco,
Tokyo, Japan). Chromatographic separation was achieved using
a Unison UK-C18 column (100 mm × 4.6 mm, 3 µm) at a
flow rate of 1 ml/min. The concentration of imatinib was then
analyzed using water/methanol/triethylamine (54:45:1) with a
pH adjusted to 4.80 ± 0.05 as the mobile phase. The detection
wavelength was set to 260 nm, and the injection volume was
50.0 µl. The striatal penetration of imatinib was assessed by
striatum-to-blood concentration ratios, according to the method
described previously (Bihorel et al., 2007).
For quantification of striatal DA and its metabolites, tissue
samples were homogenized in 500 µl of perchronic acid
(50 nM). After adding 400 µl of perchronic acid (50 nM)
and 100 µl isoproterenol (as an internal standard substance,
1 µg/ml), homogenates were incubated on ice for 30 min,
then centrifuged at 2,500 rpm for 15 min. Extracted samples
(50 µl) were quantified via HPLC with an electrochemical
detector (Eicom, Kyoto, Japan). The concentrations of DA, 3,4-
dihydroxy-phenylacetic acid (DOPAC), and homovanillic acid
(HVA) were analyzed using octane sulfonic acid (1.064 mM),
EDTA-2Na (0.013 mM), 15% methanol, and a 0.1 M sodium
citrate-0.1M sodium acetate buffer (pH 3.5) as the mobile phase.
Chromatographic separation was achieved using an Eicompak
SC-5ODS column (3.0ID × 150 mm). Concentrations of DA,
DOPAC, and HVA were expressed as µg/g of total tissue weight
(Kadoguchi et al., 2014).
Western-Blot Analysis
Mice were sacrificed by cervical dislocation 30 min after
administration of levodopa, imatinib, or vehicle. Striatal tissues
were then quickly sampled and frozen with liquid nitrogen.
Striatal tissue samples were prepared according to the Laemmli’s
method with slight modifications, as in our previous report
(Tanabe et al., 2014). Each sample, after being standardized
to contain the same amount of protein as other samples,
was subjected to 10% sodium-dodecylsulfate polyacrylamide
gel electrophoresis, followed by blotting onto a polyvinylidene
fluoride membrane. The blotted membranes were then incubated
with the desired primary antibodies. Antibodies against tyrosine
hydroxylase (TH, 1:1000; Millipore, Billerica, MA, United States),
dopamine transporter (DAT, 1:1,000; Chemicon International,
Temecula, CA, United States), vesicle monoamine transporter
2 (VMAT2, 1:500, Santa Cruz Biotechnology, Santa Cruz, CA,
United States), Cdk5-pTyr15 (1:1,000; Santa Cruz Biotechnology,
Santa Cruz, CA, United States), Cdk5 (1:1,000; Cell Signaling,
Danvers, MA, United States), DARPP-32-pThr75 (1:1,000; Cell
Signaling), DARPP-32-pThr34 (1:1,000; Cell Signaling), DARPP-
32 (1:1,000; Cell Signaling), c-Abl (1:1,000; Cell Signaling), and
c-Abl-pTyr412 (1:1,000; Cell Signaling) were used. Anti-β-actin
antibody (1:5,000; Sigma–Aldrich) was used for adjustments
to ensure that equal amounts of protein were loaded into each
well. The bound antibodies were detected by the enhanced
chemiluminescence method using horseradish peroxidase-
conjugated secondary antibodies. Gel images were captured
using a lumino-imaging analyzer LAS-4000 (Fujifilm, Tokyo,
Japan). Optical densities were evaluated using a computerized
image analysis system (Dolphin-DOC; Kurabo, Osaka, Japan).
Statistical Analysis
All experimental values were expressed as means ± SEM.
Statistical significance was evaluated by one-way analysis of
variance (ANOVA) followed by the Scheffe post hoc test for
pairwise comparisons. The significance level was set to P < 0.05.
All analysis were conducted in Stat View 5.0 (SAS Institute, Cary,
NC, United States).
RESULTS AND DISCUSSION
Striatal Penetration of Peripherally
Administered Imatinib in Naïve Mice
The blood-brain barrier (BBB), which contains various eﬄux
transporters, represents a major obstacle to the delivery of most
drugs to the central nervous system (Daneman and Prat, 2015).
All c-Abl inhibitors have a limited BBB penetrance (Lindholm
et al., 2016). Here, we used HPLC to quantify the concentrations
of imatinib in the striatum, cortex, hippocampus, thalamus,
and blood plasma from naïve mice that received a single i.p.
injection of imatinib mesylate (25 mg/kg) 30 min before sacrifice
(Figure 1A). Our results showed that the concentration of
imatinib in the striatum was 3.961 ± 0.236 µg/g of tissue
weight, in cortex was 3.198 ± 0.046 µg/g of tissue weight, in
the hippocampus was 4.806 ± 0.221 µg/g of tissue weight, in
the thalamus was 3.472 ± 0.382 µg/g of tissue weight, while
that in the blood plasma was 48.23 ± 2.51 µg/ml. Accordingly,
the striatum-to-blood concentration ratio of imatinib was
0.083 ± 0.005. Thus, peripherally administered imatinib was
partially incorporated into the striatum, as had been suggested
previously (Breedveld et al., 2005; Bihorel et al., 2007).
Systemic Administration of Imatinib
Normalizes Striatal Motor Behaviors in
MPTP-Treated Mice
We previously reported that systemic administration of
nilotinib (AMN107), a second-generation c-Abl inhibitor,
exerted an immediate, therapeutic impact on motor deficits
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FIGURE 1 | Effects of imatinib and levodopa on striatal motor behaviors and c-Abl/Cdk5/DARPP-32 signaling cascades. (A) Striatal penetration of intraperitoneally
injected imatinib in mice. HPLC analysis were done to quantify concentrations of imatinib in the striatum (n = 4), cortex (n = 5), hippocampus (n = 4), thalamus
(n = 4), and blood plasma (n = 5) of naïve mice that received single i.p. injections of imatinib mesylate (25 mg/kg) 30 min before sacrifice. Values are expressed
as means ± SEM. (B) Symptomatic antiparkinsonian effects of imatinib and levodopa in MPTP-treated mice. Behavioral tests were carried out in vehicle or
(Continued)
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FIGURE 1 | Continued
MPTP-treated mice 30 min after a single i.p. injection of imatinib and/or levodopa. (left-upper panel) The beam-walking test for examining the effects of
administration of imatinib mesylate (25 mg/kg) or levodopa (15 mg/kg). Values are means ± SEM (n = 5–21). ∗P < 0.05 versus vehicle-treated mice; one-way
ANOVA [F(5,77) = 11.265] followed by the Scheffe post hoc test. (right-upper panel) The rota-rod test for examining the effects of imatinib mesylate (25 mg/kg) or
levodopa (15 mg/kg) administration. Values are means ± SEM (n = 8–21). ∗P < 0.05 versus vehicle-treated mice; one-way ANOVA [F(5,80) = 7.710] followed by the
Scheffe post hoc test. (left-lower panel) The beam-walking test for examining the effects of imatinib mesylate (10 mg/kg) and/or levodopa (2.5 or 5 mg/kg)
administration. Values are means ± SEM (n = 10–11). #P < 0.05 versus MPTP-treated mice; one-way ANOVA [F(5,55) = 4.177] followed by the Scheffe post hoc
test. (right-lower panel) The rota-rod test for examining the effects of imatinib mesylate (10 mg/kg) and/or levodopa (2.5 or 5 mg/kg) administration. Values are
means ± SEM (n = 10–11). ###P < 0.001 versus MPTP-treated mice; one-way ANOVA [F(5,55) = 8.283] followed by the Scheffe post hoc test. (C) Western-blot
analysis of striatal levels of Cdk5-pTyr15 and Cdk5 in vehicle or MPTP-treated mice 30 min after single i.p. injections of imatinib. Values are means ± SEM (n = 4–5).
∗P < 0.05 versus vehicle-treated mice, #P < 0.05 versus MPTP-treated mice; one-way ANOVA [FCdk5−pTyr15(4,19) = 50.391, FCdk5(4,19) = 1.413] followed by the
Scheffe post hoc test. IMB (10), imatinib mesylate (10 mg/kg); IMB (25), imatinib mesylate (25 mg/kg). (D) Western-blot analysis of striatal levels of
DARPP-32-pThr75, DARPP-32-pThr34, and DARPP-32 in vehicle or MPTP-treated mice 30 min after a single i.p. injection of imatinib. Values are means ± SEM
(n = 4–5). ∗P < 0.05 versus vehicle-treated mice, #P < 0.05 versus MPTP-treated mice; one-way ANOVA [FDARPP−32−pThr75(4,19) = 35.089, F
DARPP−32−pThr34(4,19) = 0.711, FDARPP−32(4,19) = 0.293] followed by the Scheffe post hoc test. IMB (10), imatinib mesylate (10 mg/kg); IMB (25), imatinib mesylate
(25 mg/kg). (E) Western-blot analysis of striatal levels of Cdk5-pTyr15 and Cdk5 in MPTP-treated mice 30 min after a single i.p. injection of levodopa and/or imatinib.
Values are expressed as means ± SEM (n = 5–10). #P < 0.05, ##P < 0.01 versus MPTP-treated mice. One-way ANOVA [FCdk5−pTyr15(3,31) = 6.039,
FCdk5(3,17) = 0.258] followed by the Scheffe post hoc test. Levodopa (5), levodopa (5 mg/kg); IMB (10), imatinib mesylate (10 mg/kg). (F) Western-blot analysis of
striatal levels of DARPP-32-pThr75, DARPP-32-pThr34, and DARPP-32 in MPTP-treated mice 30 min after a single i.p. injection of imatinib and/or levodopa. Values
are expressed as means ± SEM (n = 4-10). #P < 0.05, ##P < 0.01 versus MPTP-treated mice. One-way ANOVA [FDARPP−32−pThr75(3,29) = 5.529,
FDARPP−32−pThr34(3,16) = 1.257, FDARPP−32(3,16) = 2.886] followed by the Scheffe post hoc test. Levodopa (5), levodopa (5 mg/kg); IMB (10), imatinib mesylate
(10 mg/kg). (G) Western-blot analysis of striatal levels of c-Abl-pTyr412, and c-Abl in MPTP-treated mice 30 min after a single i.p. injection of imatinib and/or
levodopa. Values are expressed as means ± SEM (n = 8–11). #P < 0.05 versus MPTP-treated mice; One-way ANOVA [Fc−Abl−pTyr412(3,34) = 5.820,
Fc−Abl(3,29) = 0.240] followed by Scheffe post hoc test. Levodopa (5), levodopa (5 mg/kg); IMB (10), imatinib mesylate (10 mg/kg).
in MPTP-treated mice, as assessed by the beam-walking test,
rota-rod test, bar test, horizontal-wire test, and foot-printing test
(Tanabe et al., 2014). In this study, we also performed behavioral
tests in MPTP-treated mice 30 min after administration of
imatinib and/or levodopa. The beam-walking test revealed that,
in MPTP-treated mice, an abnormal increase in the traveling time
was significantly reversed by administration of imatinib mesylate
(25 mg/kg) or levodopa (15 mg/kg) (Figure 1B, left-upper panel;
∗P < 0.05). The rota-rod test also revealed that, in MPTP-treated
mice, the latency to fall was returned to normal levels after
administration of imatinib mesylate (25 mg/kg) or levodopa
(15 mg/kg) (Figure 1B, right-upper panel; ∗P < 0.05). It was also
noted that, in MPTP-treated mice, administration of levodopa
(2.5 or 5.0 mg/kg) or imatinib mesylate (10 mg/kg) alone had
no effect on traveling time or latency to fall, as determined by
the beam-walking (Figure 1B, left-lower panel) and rota-rod
(Figure 1B, right-lower panel) tests. However, the beam-walking
test revealed that administration of levodopa (5.0 mg/kg)
combined with imatinib mesylate (10 mg/kg) significantly
reduced the traveling time in MPTP-treated mice (Figure 1B,
left-lower panel; #P < 0.05). Moreover, the rota-rod test showed
that administration of levodopa (2.5 or 5.0 mg/kg) combined
with imatinib mesylate (10 mg/kg) significantly increased the
latency to fall in MPTP-treated mice (Figure 1B, right-lower
panel; ###P < 0.001). Collectively, these findings suggest that
levodopa and imatinib synergistically improve motor deficits in
MPTP-treated mice.
Systemic Administration of Imatinib
Normalizes Striatal
c-Abl/Cdk5/DARPP-32 Signaling
Cascades in MPTP-Treated Mice
We have previously demonstrated that the immediate therapeutic
effects of c-Abl inhibitors are associated with a normalization
of altered striatal Cdk5 and DARPP-32 signals in MPTP-treated
mice (Yamamura et al., 2013; Tanabe et al., 2014). c-Abl is known
to phosphorylate Cdk5-Tyr15 and thereby facilitates Cdk5
activity (Zukerberg et al., 2000; Dhavan and Tsai, 2001; Zhang
et al., 2007). In normal mice, Cdk5-pTyr15 is highly enriched
in the striatum (Morigaki et al., 2011), where dopaminergic
stimulation inhibits phosphorylation of Cdk5-Tyr15 via the D2-
type dopamine receptors (Yamamura et al., 2013). In the striatum
of MPTP-treated mice, DA deficiency causes an increased
phosphorylation of both Cdk5-Tyr15 and DARPP-32-Thr75,
which is reversed by c-Abl inhibition (Yamamura et al., 2013).
Here, we reappraised the effects of c-Abl inhibition on striatal
c-Abl/Cdk5/DARPP-32 signaling cascades in MPTP-treated mice
30 min after administration of imatinib and/or levodopa.
Western-blot analysis revealed a significant increase in striatal
levels of Cdk5-pTyr15 (Figure 1C; ∗P < 0.05) and DARPP-
32-pThr75 (Figure 1D; ∗P < 0.05) in MPTP-treated mice as
compared with vehicle-treated mice, which was reversed by the
administration of imatinib mesylate in a dose dependent manner
(10 and 25 mg/kg, Figures 1C,D; #P < 0.05). It was also noted
that in MPTP-treated mice, an abnormal increase in striatal levels
of Cdk5-pTyr15 was significantly reduced by administration of
imatinib mesylate (10 mg/kg) alone (Figures 1C,E; #P < 0.05) or
imatinib mesylate (10 mg/kg) combined with levodopa (5 mg/kg)
(Figure 1E; ##P < 0.01). Administration of levodopa (5 mg/kg)
alone had no effect on striatal levels of Cdk5-pTyr15 (Figure 1E).
In parallel, an abnormal increase in striatal levels of DARPP-32-
pThr75 was significantly reduced by administration of imatinib
mesylate (10 mg/kg) alone (Figures 1D,F; #P < 0.05), levodopa
(5.0 mg/kg) alone, or imatinib mesylate (10 mg/kg) combined
with levodopa (5.0 mg/kg) (Figure 1F; #P < 0.05, ##P < 0.01).
Administration of imatinib mesylate (10 mg/kg) alone, levodopa
(5.0 mg/kg) alone, or imatinib mesylate (10 mg/kg) combined
with levodopa (5.0 mg/kg) has no effect on striatal levels
of DARPP-32-pThr34 (Figure 1F). Moreover, striatal levels
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FIGURE 2 | Effects of imatinib on striatal presynaptic dopaminergic markers in MPTP-treated mice. Western-blot and HPLC analyses were carried out on the striatal
extracts from vehicle or MPTP-treated mice 30 min after a single i.p. injection of imatinib mesylate (10 or 25 mg/kg). (A) Western-blot analysis of striatal levels of TH.
Values are means ± SEM (n = 4-5). ∗P < 0.05 versus vehicle-treated mice; one-way ANOVA [F(4,19) = 107.43] followed by the Scheffe post hoc test. IMB (10),
imatinib mesylate (10 mg/kg); IMB (25), imatinib mesylate (25 mg/kg). (B) Western-blot analysis of striatal levels of DAT. Values are means ± SEM (n = 4–5). ∗P < 0.05
versus vehicle-treated mice; one-way ANOVA [F(4,19) = 21.749] followed by the Scheffe post hoc test. IMB (10), imatinib mesylate (10 mg/kg); IMB (25), imatinib
mesylate (25 mg/kg). (C) Western-blot analysis of striatal levels of VMAT2. Values are means ± SEM (n = 4–5). ∗P < 0.05 versus vehicle-treated mice; one-way
ANOVA [F(4,19) = 20.615] followed by the Scheffe post hoc test. IMB (10), imatinib mesylate (10 mg/kg); IMB (25), imatinib mesylate (25 mg/kg). (D–G) HPLC
analysis of striatal levels of DA (D), DOPAC (E), HVA (F), and DA-turnover, which represents a net dopamine usage in striatum with (DOPAC + HVA)/DA (G). Values
are expressed as means ± SEM (n = 4–5). ∗P < 0.05 versus vehicle-treated mice; one-way ANOVA [FDA(4,19) = 34.526, FDOPAC(4,19) = 15.383, FHVA(4,19) = 16.078,
FDA− turnover(4,19) = 10.355] followed by the Scheffe post hoc test. IMB (10), imatinib mesylate (10 mg/kg); IMB (25), imatinib mesylate (25 mg/kg).
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FIGURE 3 | Hypothetical scheme showing symptomatic antiparkinsonian effects of c-Abl inhibitors. Depicted are the possible roles of c-Abl inhibitors at
post-synaptic levels in the striatum. In the postsynaptic medium spiny neurons, dopamine deficiency may induce c-Abl activation to increase phosphorylation of
Cdk5 at Tyr15 (Cdk5-Tyr15) and DARPP-32 at Thr75 (DARPP-32-Tyr75), resulting in an increased activity of the Cdk5/DARPP32-Thr75 pathway, which leads to
parkinsonian symptoms. Thus, c-Abl inhibitors may exert symptomatic antiparkinsonian effects at the post-synaptic level. PD, Parkinson’s disease; D1R, D1-type
dopamine receptor; D2R; D2-type dopamine receptor; Cdk5-pTyr15, Cdk5 with tyr15 phosphorylation; T34, Threonine 34; T75, Threonine 75.
of c-Abl-pTyr412, an active form of c-Abl (Brasher and Van
Etten, 2000), were significantly reduced by the administration
of imatinib mesylate (10 mg/kg) combined with levodopa
(5.0 mg/kg) in MPTP-treated mice (Figure 1G; #P < 0.01). Thus,
imatinib showed an inhibitory effect on the Cdk5/DARPP-32-
signaling pathway in the striatum, as did levodopa.
No Effects of Imatinib on Striatal
Presynaptic Dopaminergic Markers in
MPTP-Treated Mice
We also examined the effects of c-Abl inhibition on striatal
presynaptic dopaminergic markers in MPTP-treated mice 30 min
after administration of imatinib. Western-blot analysis revealed
that striatal levels of TH (Figure 2A, ∗P< 0.05), DAT (Figure 2B,
∗P< 0.05), and VMAT2 (Figure 2C, ∗P< 0.05) were significantly
lower in the MPTP-treated mice than in the vehicle-treated mice.
Notably, administration of imatinib mesylate (10 or 25 mg/kg)
had no effects on striatal levels of TH, DAT, or VMAT2 in
either normal or MPTP-treated mice (Figures 2A–C). HPLC
analysis also revealed a significant reduction in striatal levels of
DA (Figure 2D; ∗P < 0.05), DOPAC (Figure 2E; ∗P < 0.05),
and HVA (Figure 2F; ∗P < 0.05) in MPTP-treated mice when
compared to vehicle-treated mice. We found that administration
of imatinib mesylate (10 or 25 mg/kg) had no effects on striatal
levels of DA, DOPAC, or HVA in MPTP-treated mice, as in
normal mice (Figures 2D–F). Striatal DA-turnover, as calculated
by dividing the total amount of DOPAC and HVA by DA content,
was significantly increased in MPTP-treated mice (Figure 2G;
∗P < 0.05) as compared to vehicle-treated mice. We found
that administration of imatinib mesylate (10 or 25 mg/kg) had
no effects on striatal DA-turnover in either normal or MPTP-
treated mice (Figure 2G). Taken together, these results suggest
that the immediate therapeutic effects of imatinib in MPTP-
treated mice depend on postsynaptic, but not presynaptic, striatal
mechanisms.
CONCLUSION
Our results demonstrate that, in MPTP-treated mice, imatinib
has a therapeutic effect on abnormal motor behaviors within
an hour after its systemic administration. This symptomatic
therapeutic action is associated with a normalization of otherwise
increased phosphorylation of striatal Cdk5-Tyr15 and DARPP-
32-Thr75, but has no effects on striatal presynaptic dopaminergic
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markers. As a major striatal postsynaptic mechanism, DA and
glutamate signals have been demonstrated to play opposing
physiological roles via a positive feedback loop that amplifies
their mutually antagonistic actions (Greengard, 2001). Given
this, glutamate inputs could activate Cdk5, leading to increased
phosphorylation of DARPP-32-Thr75 and thereby antagonizing
striatal DA functions (Bibb et al., 1999). Although the precise
mechanism by which c-Abl activity involves interactions between
DA and glutamate transmission in the striatum remains
unknown, land mark reports demonstrated that c-Abl could
phosphorylate Cdk5-Tyr15 to increase Cdk5 activity (Zukerberg
et al., 2000; Zhang et al., 2007). Based on a series of
studies conducted by our group, including the one presented
here, we hypothesize that c-Abl inhibition exerts symptomatic
antiparkinsonian actions via inhibition of phosphorylation of
Cdk5-Tyr15, thereby, resulting in decreased activity of the
striatal glutamate/Cdk5/DARPP-32 pathway (for reference see
Figure 3). Further studies with targeting these molecules would
clarify the consequence between them and PD-related motor
symptoms. Together with additional intriguing evidence that
c-Abl inhibition may exert disease-modifying effects on PD
by playing a protective role against the degeneration of nigral
dopaminergic cells (Ko et al., 2010; Imam et al., 2011, 2013;
Hebron et al., 2013a,b), we suggest that c-Abl inhibitors may
serve as an alternative agent for attenuating motor symptoms
and disease progression in patients with PD. However, the c-Abl
inhibitors currently approved for use in clinics have limited
BBB penetrance (Lindholm et al., 2016), as demonstrated here
for imatinib, which may limit their clinical utility. In addition,
although some c-Abl inhibitors are widely used in the treatment
of chronic myelocytic leukemia, the potential risk that they pose
for causing serious systemic adverse effects has been reported
(Arora and Scholar, 2005). The development of new therapeutic
interventions to deliver c-Abl inhibitors to specific brain regions
may be needed for their long-term use in the treatment of PD.
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